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Inflammatory Response in Equine Joints. Studies on 
Proinflammatory Cytokines in Diseased Joints and Chondrocyte 
Cultures 
Abstract 
Proinflammatory cytokines mediate inflammatory responses as well as regulate tissue 
metabolism. Thus, they may provide a link between inflammation and other 
pathologic findings seen in equine joint disease. The aims of this thesis were to gain 
a deeper understanding of the development of chondral pathology in equine 
osteoarthritis (OA) by obtaining increased knowledge of inflammatory processes in 
the joint, and to investigate proinflammatory cytokines as markers of joint 
pathology. 
Measurements of interleukin (IL)-6 and tumour necrosis factor (TNF) activities 
in synovial fluid from clinical cases of carpal joint disease revealed increased 
concentrations of bioactive IL-6 in joints with osteochondral fragments (OCF). 
Immunohistochemical staining for IL-6 and high mobility group box protein 
(HMGB)-1 in tissues from diseased carpal and fetlock joints identified both OCF 
and synovial membranes as cellular sources of IL-6 and extracellular/cytoplasmic 
HMBG-1. Histological assessment of synovial membrane biopsies from 
immunostained joints showed increased grade of synovitis in diseased compared to 
healthy joints. The effects of IL-6, IL-1β and HMGB-1 on chondrocyte 
metabolism was studied in vitro, and focused on gene expression analyses. A 
catabolic response to IL-1β was detected, whereas the response to IL-6 and 
HMGB-1 was varied but indicated promotion of cartilage formation. Analyses of 
the ultrastructural immunolocalisation of HMGB-1 in IL-1β and IL-6 treated 
pellets, showed a trend for decreased nuclear/cytoplasmic ratio, and increased 
extracellular matrix density of HMGB-1 after IL-6 treatment. 
Theses studies gained insight to presence of TNF, IL-6 and HMGB-1 in equine 
joints, and indicated an increased inflammatory response in joints with OCF. The 
difference in metabolic response of chondrocytes to IL-1β versus IL-6 or HMGB-1 
in vitro, and differences in HMGB-1 translocation after IL-1β and IL-6 treatment 
suggest that the outcome of cartilage pathology in equine joint disease may relate to 
the individual contributions of cytokine activity and cytokine interactions. 
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1  Introduction 
1.1  General background 
Traumatically induced arthritis is a common cause of joint disease in athletic 
horses and is associated with numerous conditions, including traumatic 
synovitis and capsulitis, ligamentous or meniscal injuries, subchondral bone 
disease, osteochondral fractures and osteoarthritis (McIlwraith, 2001). A 
recent study showed that 11 and 13% of  ailments in two and three year old 
Thoroughbred horses, respectively, related to joint problems (Wilsher et al., 
2006). In athletic horses, the carpal and fetlock joints are often involved, and 
accounted (in equal parts) for 28% of cases with lameness resulting in lost 
days of training in Thoroughbred racehorses (Rossdale et al., 1985). 
Furthermore, middle carpal lameness has been reported to develop in 30% 
of Standardbred horses during their first 12-18 months of training (Hopper 
et al., 2004), and was the most common cause for extended rest (Steel et al., 
2006). However, also in non-racing horses joint problems are common. A 
Swedish study on cause-specific morbidity, based upon insurance company 
data on non-racing horses between 1997-2000, showed that the joints were 
the most commonly affected part of the body, and that fetlock arthritis was 
the most common diagnosis (Penell et al., 2005).  
Joint lesions involving the articular cartilage pose special concerns as the 
adult articular cartilage shows little capacity for intrinsic healing, and 
satisfactory repair of the tissue is difficult to achieve (Nixon & Fortier, 2001; 
Buckwalter et al., 1990; Convery et al., 1972). In addition, subtle or early 
changes of cartilage disease are difficult to diagnose with routinely available 
clinical aids. When cartilage lesions of training and racing horses are 
diagnosed concurrent bone and soft tissue changes are commonly present 
(Pool & Meagher, 1990), making it difficult to determine the sequence of   12 
events in the diseased joint. As any traumatic injury will initiate an 
inflammatory response, studies of inflammatory processes in joint tissues may 
increase the understanding of the mechanisms contributing to cartilage 
damage and increase the possibilities to detect early pathologic changes in 
the cartilage, thereby preventing chronic and irreversible joint disease. 
1.2  The carpal and fetlock joints 
Joints are formed by unions of bone or cartilage by other tissue. The carpal 
and fetlock joints are diarthrodial joints, i.e. movable joints that demonstrate 
a joint cavity (containing synovial fluid), a lining of synovial membrane, and 
articular cartilage (Sisson, 1953). However, the subchondral bone and other 
structural elements, such as muscles, tendons, ligaments, bursae and menisci 
are also required to provide appropriate joint function (Sledge et al., 2001). 
The carpal joint consists of three major compartments and two rows of 
carpal bones. The proximal row include the radial, intermediate, ulnar and 
accessory carpal bones, and the distal row the first (sometimes missing) 
second, third, fourth and fifth (often missing) carpal bones (Butler et al., 
2000). In addition to several peri- and intra-articular ligaments, the proximal 
and distal rows of the carpal bones are connected via the medial and lateral 
palmar intercarpal ligaments. The medial palmar intercarpal ligament 
attaches proximally to the radial carpal bone and distally to the second and 
third carpal bones (C3) (Whitton et al., 1997b; Phillips & Wright, 1994). 
The lateral palmar intercarpal ligament, attaches proximally to the ulnar and 
intermediate carpal bones and distally to C3 and the fourth carpal bone 
(Whitton et al., 1997b; Phillips & Wright, 1994) (Fig. 1). The palmar 
intercarpal ligaments have been proposed to absorb loads created by medial 
to lateral displacement of the carpal bones during axial weight bearing 
(Bramlage et al., 1988), but they also prevent dorsal displacement of the 
proximal row of carpal bones (Whitton & Rose, 1997). 
The large amount of traumatic injuries seen in the dorsal parts of the 
radiocarpal and middle (inter-) carpal joint may partly relate to altered 
contact and pressure patterns seen with increased mechanical loading, as 
described for C3 (Palmer et al., 1994). In addition, fractures arise as 
strenuous exercise exposes the dorsal margins of the bones of the intercarpal 
joint to harmful forces when they come together with sudden focal high 
impact, or the dorsal margins of the bones of the radiocarpal joint are 
brought together when the joint is overrotated at high racing speed 
(Bramlage, 1983). 
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Figure 1. Line drawings of the articular surfaces of the upper (radiocarpal, A) and middle 
(intercarpal, B) compartments of the equine carpus. (A) Ca = accessory carpal bone; Ci = 
intermediate carpal bone; Rc = radial carpal bone; Ra = radius. (B) C2 = second carpal 
bone, C3 = third carpal bone; C4 = fourth carpal bone; LPICL = lateral palmar intercarpal 
ligament; MPICL = medial palmar intercarpal ligament. (Drawings by Karolina Larsson.) 
The fetlock joints (metacarpo-/metatarsophalangeal joints) are formed by 
the distal third metacarpal/metatarsal bone, the proximal part of the 
proximal phalanx, and the two proximal sesamoid bones, embedded in the 
intersesamoidean ligament (Fig. 2). The joint has a thick joint capsule, 
several external ligaments, including the suspensory ligament (Sisson, 1953).   14 
It has been proposed that the joint is particularly susceptible to traumatic 
injury due to its small surface area, its great range of motion, and its role in 
weight transmission during stride (Pool & Meagher, 1990). The contact area 
between the third metacarpal bone and the proximal phalanx is increased 
with loading, and the highest pressures are created at the dorsal articular 
margins (Brama et al., 2001), which is a common location for osteochondral 
pathology (Pool & Meagher, 1990). 
 
Figure 2. Line drawing of the articular surfaces of the equine metacarpo-/metatarsophalangeal 
joint. Mc/Mt3 = third metacarpal/-tarsal bone; Ps = proximal sesamoid bones; P1 = 
proximal phalanx. (Drawings by Karolina Larsson.) 
1.3  Joint structures 
The joint can only properly operate as an organ when the articular tissues 
are in metabolic balance, and provide appropriate interaction with each 
other. In this section, breif descriptions of components (Fig. 3A-C) and 
functions of the tissues of the synovial joints are given. 
1.3.1  Osteochondral tissues 
Articular cartilage provides low friction movements between bones, and 
absorbs and distributes mechanical loads applied to the joint. It is composed 
of extracellular matrix (ECM), matrix water, and a small proportion of 
chondrocytes, which are responsible for matrix synthesis and metabolic 
homeostasis. The main structural components of the ECM are collagens   15 
(approximately 60% of the dry weight of the cartilage), proteoglycans (25-
30% of the dry weight) and non-collagenous proteins and glycoproteins (15-
20% of the dry weight) (Buckwalter & Hunziker, 1999). 
The collagen framework provides the cartilage with tensile strength. 
Collagen type II, the principal collagen in articular cartilage, is arranged in 
crosslinked triple helices and form a fibrillar network together with smaller 
amounts of other types of collagens, such as type IX, XI, III and V (Sandell 
et al., 2007). In addition, collagen type VI is found in the pericellular matrix 
and may bridge the chondrocyte to surrounding ECM (Poole et al., 1992). 
Proteoglycans provide the cartilage with compressive properties, due to 
their negatively charged glycosaminoglycan (GAG) side chains, which attract 
water by creating a large osmotic swelling pressure (Kiani et al., 2002). The 
chondroitin sulphate rich proteoglycan aggrecan is the dominating 
proteoglycan in articular cartilage, and it binds to hyaluronan to form large 
aggregates (Kiani et al., 2002). 
In addition, the ECM contains a large number of proteins, several 
belonging to the family of leucine- rich repeat proteins, which may bind to 
collagens and membrane molecules (integrins), and the family of 
thrombospondins, including the collagen binding glycoprotein cartilage 
oligomeric matrix protein (COMP) (Sandell et al., 2007).  
The adult articular cartilage is avascular, alymphatic and aneural, and 
relies upon nourishment from the synovial fluid and the vasculature of the 
subchondral bone (Goldring & Goldring, 2005). Morphologically articular 
cartilage is divided into four zones: superficial, intermediate, deep and 
calcified (Fig. 3B). The superficial zone shows chondrocytes with a flattened 
cellular shape, low proteoglycan content and abundant collagen fibrils, 
arranged parallel to the cartilage surface. In the intermediate zone cells 
become more spheroid, the collagen fibrils thinner and more dispersed and 
proteoglycan content increased. In the deep zone chondrocytes are arranged 
perpendicular to the joint surface, thick collagen fibrils run parallel to 
chondrocyte orientation and proteoglycan content is high (Goldring & 
Goldring, 2005). Influences on the biochemical content of cartilage from 
site and/or exercise has been demonstrated in several equine studies of carpal 
cartilage (Murray et al., 2001a; Murray et al., 2001b; Murray et al., 2000; 
Palmer et al., 1995a), as well as in cartilage from the proximal phalanx 
(Brama et al., 2009; Brama et al., 2002; Brama et al., 2000a; Brama et al., 
2000b; Brama et al., 2000c; Brama et al., 1999) and the third metacarpal 
bone (Brama et al., 2000c).  
The so called tidemark provides a demarcation between non-calcified 
and calcified cartilage (Fig. 3B). The tidemark can be distinguished due to its   16 
enhanced metachromatic staining pattern, and has been suggested to be the 
result of the accumulation of nuclear debris (Simkin, 2008) and non-specific 
molecules caused by discontinuous mineralisation (Oegema et al., 1997). 
The zone of calcified cartilage is located between the tidemark and the 
subchondral bone. Its boundaries are determined by the moving of the 
tidemark into the non-calcified cartilage and by replacement of calcified 
cartilage by subchondral bone. Increased thickness of the calcified cartilage 
has been reported in carpal cartilage from horses subjected to high intensity 
exercise compared to walking exercise (Murray et al., 1999). The zone of 
calcified cartilage is involved in force transmission and dissipation at the 
bone-cartilage interface and constitutes a diffusion barrier between the bone 
and non-calcified articular cartilage (Oegema et al., 1997). As indicated from 
ultrastructural studies, chondrocytes of the calcified cartilage have little 
metabolic activity (Buckwalter & Hunziker, 1999). 
The subchondral bone absorbs mechanically induced stresses to provide 
cushioning for the joint, and ensure maintenance of an incongruent joint 
surface (Kawcak et al., 2001). The subchondral bone is composed of a 
cortical bone plate (compact bone) and of trabecular (cancellous) bone. 
Bone is continuously transformed in response to loading conditions, and its 
strength depends on material properties as well as structural arrangement 
(Burr, 2004). Influence from loading on bone characteristics in horses has 
been demonstrated in the C3 and the radial carpal bone, where increased 
bone formation, remodeling and collagen synthesis was found in racing 
horses compared to non-racing horses (Tidswell et al., 2008). In studies of 
the distal equine third metacarpal bone, a sagittal direction of main 
trabeculae of the subchondral cancellous bone and less significant 
connections mediolaterally was demonstrated, suggesting maximum stiffness 
in the direction of the greatest peak loads (Boyde et al., 1999). Bone 
formation is carried out by osteoblasts, which synthesize osteoid that 
subsequently is mineralised, whereas bone resorption involves the 
breakdown of mineralised tissue by osteoclasts (Schenk et al., 2002). 
1.3.2  Joint capsule and ligaments 
The outer parts of the joint capsule and the ligaments have joint stabilizing 
function. Ligaments share macroscopic similarities with tendons but the 
biochemical and structural composition differ (Rumian et al., 2007; Amiel et 
al., 1984), so that ligaments can withstand high tensile forces applied in 
multiaxial patterns. Bundles of collagen (predominanty collagen type I) are 
arranged in a wavy “crimp” pattern, with a relatively higher collagen type 
III conent in ligaments compared to tendons (Amiel et al., 1984).   17 
The internal part of the joint capsule, i.e. the synovial membrane or 
synovium, produces components of the synovial fluid and provides nutrients 
for the articular cartilage. It may form villous projections into the joint 
cavity. Cells of the inner cellular lining layer (synovial intima) consist of 
macrophage-derived type A synoviocytes (Fig. 3C) with phagocytic and 
antigen presenting abilities, fibroblast-derived secretory type B synoviocytes, 
and transitional forms thereof (type C cells) (Goldring & Goldring, 2005; 
Iwanaga et al., 2000). In the sublining tissue (synovial stroma or subintima) 
cells are predominantly fibroblasts. In the horse, three types of synovial 
membrane are recognized depending on the structure of the underlying 
stroma; areolar (characterized by loose connective tissue), adipose and 
fibrous (Johansson & Rejno, 1976), and four types of villi (bell, tongue, leaf 
and sword type) have been identified, distinguished by their shape and 
length (Izumisawa et al., 1996). A predominance of type A synoviocytes has 
been reported in synovial villi from fetlock joints (Izumisawa et al., 1996), 
although another study showed a predominance of type B synoviocytes in 
healthy fetlock, hock and stifle joints, with a relative increase in type A cells 
in diseased joints (Johansson & Rejno, 1976). In carpal joints, type A 
synoviocytes were mainly localised at the tip of the villi and type B 
synoviocytes showed a more even distribution (Shikichi et al., 1999). 
 
Figure 3. (A) Sagittal section of a synovial joint (radiocarpal joint), showing joint capsule (jc), 
articular cartilage (ac) and subchondral bone (sc). (B) Photomicrograph of articular cartilage, 
showing the cartilage zones (superficial = sz; intermediate = iz; deep = dz; calcified = cz). 
(C) Photomicrograph of synovial membrane immunostained for the macrophage marker 
CD163, showing presence of numerous type A synoviocytes in the lining layer (arrows).   18 
1.3.3  Synovial fluid 
Synovial fluid provides nutrients and lubrication for the articular cartilage. It 
is formed by an ultrafiltrate of plasma and locally produced substances. 
Hyaluronan, synthezised by type B synoviocytes, provides the viscoelastic 
properties of synovial fluid, and is involved in cartilage lubrication, 
restriction of plasma proteins from the synovial fluid, and retention of 
synovial fluid water (Ghosh & Guidolin, 2002). In addition, lubrication is 
provided by lubricin (Swann et al., 1985; Swann et al., 1981), which is 
synthesized by synovial fibroblasts (Jay et al., 2000), and the highly 
homologous proteoglycan superficial zone protein (Neu et al., 2007; Jay et 
al., 2001), produced by chondrocytes of the superficial zone of the articular 
cartilage (Schumacher et al., 1994). 
Whereas red blood cells are not normally present in equine synovial fluid, 
the leukocyte count varies between joints (Persson, 1971). However, more 
recent literature on equine synovial fluid gives a general reference of 50-500 
leukocytes/µl, with less than 10% neutrophils (Caron, 2003). Concentrations 
of proteins in synovial fluid are dependent of several factors; plasma 
concentration, synovial blood flow, microvascular permeability, lymphatic 
drainage, local protein production and degradation (Goldring & Goldring, 
2005). However, total protein concentrations in equine synovial fluid 
normally do not exceed 2.5 g/dl (Caron, 2003; McIlwraith, 1980). 
1.4  Definition and aetiology of osteoarthritis (OA) 
In humans, OA has been defined as a group of diseases sharing similar 
biological, morphological and clinical outcomes (Flores & Hochberg, 2003). 
It has been classified as either idiopathic (primary) or secondary, with the 
former further categorized as localised or generalised (Flores & Hochberg, 
2003). However, the existence of primary OA is debated, and it has been 
suggested that OA should be viewed as a process representing the 
pathophysiological response of the joint to mechanical insults (Brandt et al., 
2008). The term OA points out involvement of subchondral bone, and the 
suffix -itis implies an inflammatory component of the disease. 
Equine OA has been described as the common end stage of a group of 
disorders characterized by progressive and permanent deterioration of the 
articular cartilage, accompanied by changes in the subchondral bone and 
articular soft tissues (McIlwraith, 2002; McIlwraith, 1996). Further 
classification of equine OA into three types was proposed by McIlwraith 
(1996); type I, associated with synovitis and capsulitis, and commonly seen 
in carpal, fetlock, distal tarsal and distal interphalangeal joints; type 2,   19 
associated with (and usually secondary to) other identified injuries or 
problems; type 3, incidental or non-progressive cartilage erosion. Other 
terms commonly used for OA include degenerative joint disease and 
osteoarthrosis. 
Repeated microtrauma caused by mechanical forces has been suggested 
to be the major aetiology of equine OA (Caron, 2003). Whether the 
articular cartilage is primary affected, or cartilage lesions arise secondary to 
changes in other tissues (subchondral bone or synovial membrane) has not 
been clarified. Increased bone stiffness and reduced load absorbing capability, 
seen as a result of suboptimal healing and remodeling of mechanically 
induced subchondral microfractures, may expose the cartilage to harmful 
stresses when normal deformation of the bone-cartilage zone fails (Caron, 
2003). Furthermore, microcracks in the calcified cartilage and subchondral 
bone are thought to trigger reactivation of secondary centers of ossification, 
resulting in advancement and reduplication of the tidemark and thinning of 
the articular cartilage, with increases in shear stresses at the base of the 
cartilage and loss of cartilage as result (Burr & Radin, 2003).  
In addition, synovitis is usually present in equine OA (McIlwraith, 1996), 
and may precede cartilage degeneration in carpal and fetlock joints of racing 
horses (McIlwraith, 1982). Several theories on how soft tissue injuries may 
contribute to OA exist, and include induction of joint instability, 
impairment of synovial capillary blood flow and reperfusion injury, and 
production of inflammatory mediators and degradative enzymes in 
mechanically damaged tissues (McIlwraith, 1996). 
1.5  Inflammation and OA 
Traditionally regarded inflammation is a reaction of vascularised tissues to 
infection or injury. Optimally, the inflammatory processes provide 
protection of the individual, and contribute to processes promoting healing.  
As part of the early (acute) inflammatory response there is vascular 
adaptation to increase blood flow, vascular permeability and recruitment of 
leukocytes, processes that are regulated by a large number of the soluble 
mediators, including vasoactive amines (eg histamine and serotonin), 
arachidonic acid metabolites (prostaglandins, leukotrienes and lipoxins), 
platelet-activating factor, reactive oxygen species, nitric oxide, cytokines and 
chemokines (Kumar et al., 2010). Cytokines act as signalling molecules 
inducing a cellular response after binding to their appropriate receptors. The 
fine tuning of their biological actions are promoted by cytokine networks, 
intricately regulated by receptor antagonists, soluble receptors, cytokines   20 
with opposing effects and decoy receptors (Balkwill, 2001). Chronic 
inflammation, morphologically characterized by neovascularisation, 
involvement of mononuclear inflammatory cells and fibrosis may occur with 
extensive tissue destruction, involvement of tissues incapable of 
regeneration, and failure of the early inflammatory response to resolve 
(Kumar et al., 2010). 
Studies of inflammation in OA provide special concerns, as the articular 
cartilage is not a vascularised tissue. Morphologically, inflammation may be 
present in the synovial membrane, and synovitis is not an uncommon 
finding in either equine (McIlwraith, 1996) or human OA (Haywood et al., 
2003; Smith et al., 1997; Goldenberg et al., 1982). Increased mononuclear 
infiltrates, blood vessel formation, and numbers of synovial lining layers have 
been reported in early (duration < 1 year) human OA compared to late 
stages (Benito et al., 2005). Another human study reported the most 
pronounced inflammatory changes in synovial membrane from patients with 
severe OA; however, overlap of morphological findings in the synovial 
membrane was seen between different grades of OA, and between normal 
and OA joints (Smith et al., 1997). In naturally occurring equine joint 
disease, it was reported that synovitis and articular cartilage lesions often 
were of comparable grades (Ronéus et al., 1997), however synovial 
membrane biopsies have also been found to be non-specific diagnostically 
(Trotter & McIlwraith, 1996). Short (84 days post trauma) and long (180 
days post trauma) term studies of experimental impact-induced OA in the 
horse revealed few changes in synovial membranes, with minor infiltration 
of inflammatory cells (Bolam et al., 2006). No difference in synovitis was 
found between OA and control joints in an instability-induced equine OA 
model (Simmons et al., 1999). Similar findings are described in mechanically 
induced experimental OA in rabbits, where only synovial hyperplasia 
(without other morphologic signs of inflammation) was noted to precede 
cartilage destruction (Walker et al., 1991). 
However, inflammation on a molecular level may be present in OA 
joints. Initial stages of OA are characterized by increased metabolic activity 
of chondrocytes, including cell proliferation, increased synthesis of growth 
factors and matrix proteins, but also by production of proinflammatory 
cytokines and other inflammatory mediators (Goldring & Goldring, 2007), 
and with disease progression catabolic processes, which may be induced by 
inflammatory mediators, become dominating (schematically outlined in Fig. 
4). 
The proinflammatory cytokines interleukin (IL)-1 beta (β) and tumour 
necrosis factor (TNF) alpha (α) have been suggested to be of major   21 
importance in the development of human OA (Pelletier et al., 2001). They 
are thought to influence the disease by inducing production of other 
inflammatory mediators, including prostaglandin E2 (PGE2), nitric oxide, 
IL-6, IL-8, IL-17, IL-18, leukemia inhibitory factor, and matrix degrading 
enzymes, and suppressing genes associated with differentiated chondrocytes 
(Goldring & Goldring, 2007). IL-1 (α and/or β) and TNFα induce similar 
activities on articular tissues, including leukocyte infiltration (Henderson & 
Pettipher, 1989), inhibition of proteoglycan synthesis (Wilbrink et al., 1991), 
and induction of collagenase and PGE2 production in synovial cells 
(Hauptmann et al., 1991; Lotz & Guerne, 1991). However, IL-1 has been 
shown to be considerably more potent than TNFα, and together they can 
show synergistic effects (Wilbrink et al., 1991; Henderson & Pettipher, 
1989). Apoptotic effects of IL-1 and TNFα on chondrocytes in vitro have 
been described (Kim et al., 2010; Schuerwegh et al., 2003), although 
conflicting results have been reported by others (Relić et al., 2002; Kühn et 
al., 2000; Blanco et al., 1995). Several other proinflammatory cytokines, 
such as IL-6 and IL-17, have also been discussed to be involved in the 
process of cartilage destruction in OA (Malemud, 2004). 
Matrix metalloproteinases (MMP)s, which traditionally can be 
subgrouped according to their substrates into collagenases, gelatinases and 
stromelysins, appear to be important matrix degrading agents contributing to 
cartilage loss in OA (Poole et al., 2007). In particular, MMP-13 may be 
important in cleaving collagenase type II (Knäuper et al., 1996), however 
also MMP-1, -3 and -8 are found in OA cartilage (Tetlow et al., 2001). In 
addition, the aggrecanases ADAMTS (a disintegrin and metalloproteinase 
with thrombospondin motifs)-4 and -5, have been shown to cleave aggrecan 
in several sites, and are proposed to be important in early stages of OA 
(Huang & Wu, 2008). 
Several equine studies have investigated presence of MMP activities in 
naturally occurring joint disease. In such studies, OA has sometimes been 
grouped together with other types of aseptic joint disease, leaving levels in 
OA joints not further specified. Increased synovial fluid MMP activity 
(Brama et al., 1998), and activities of MMP-1 (collagenase I) and -3 
(stromelysin I) have been detected in osteoarthritic equine joints (Brama et 
al., 2004; Brama et al., 2000d). In addition, increased synovial fluid activities 
of MMP-2 (gelatinase A) and -9 (gelatinase B) in aseptic arthritic joints 
(including OA, articular fractures, osteochondrosis dissecans and traumatic 
arthritis) have been found (Clegg et al., 1997). Although in another study, 
presence of MMP-2 and -9 in synovial fluid in aseptic joint disease 
(including acute and chronic traumatic arthritis and osteochondrosis   22 
dissecans) was mainly related to the detection of pro-forms and less often to 
active enzymes (Trumble et al., 2001). Furthermore, increased synovial fluid 
activity of MMP-9 was found in equine joints with severe cartilage lesions 
related to OA, osteochondrosis or enlarged synovial fossae (Jouglin et al., 
2000). Activity of tissue inhibitor of MMPs (TIMP)s has been demonstrated 
in normal and arthritic equine joints, with increased activity in aseptic joint 
disease (Clegg et al., 1998). 
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Figure 4. Simplified schematic description of metabolic processes in traumatically induced 
osteoarthritis. 
The work included in this thesis focused on the following proinflammatory 
cytokines: TNF, IL-6, IL-1 and high mobility group box protein (HMGB)-
1. Thus, these inflammatory mediators will be discussed in further detail. 
1.6  Interleukin-1 
IL-1 belongs to the interleukin-1 cytokine family, which currently consists 
of 11 members (Dinarello, 2009). IL-1β, as well as IL-1α and IL-1 receptor 
antagonist (IL-1Ra) binds to the IL-1 receptors (IL-1R) I and II. IL-1RI is   23 
found on most cells, and signalling is induced by IL-1α and IL-1β, but not 
by IL-1Ra (Arend, 2002). IL-1RII is found mainly on neutrophils, 
monocytes/macrophages and B-lymphocytes, and functions as a decoy-
receptor (Colotta et al., 1993). IL-1 activity is further regulated by the 
soluble forms of IL-1RI and IL-1RII, and soluble IL-1R accessory protein 
(Jacques et al., 2006). Precursor IL-1β is processed by caspase-1 (also known 
as IL-1β converting enzyme) and other non-caspase-1 mechanisms to form a 
biologically active protein (Dinarello, 2009; Dinarello, 1998), which in 
horses is proposed to have a molecular mass of 17,300 Da (Howard et al., 
1998) and show 66.4-66.7% amino acid homology with human IL-1β 
(Howard et al., 1998; Kato et al., 1995).  
Increased bioactivity of IL-1 has been detected in various equine joint 
conditions including OA (Alwan et al., 1991b; Morris et al., 1990), and IL-
1β has been demonstrated in articular cartilage from OA affected equine 
joints (Weaver et al., 2006). Messenger ribonucleic acid (mRNA) expression 
for IL-1α and β has been detected in synovial membrane and articular 
cartilage from joints with acute and chronic traumatic disease, as well as 
from normal joints (Trumble et al., 2001), and in experimentally induced 
synovitis immunostaining for IL-1β was increased in cartilage and synovial 
membrane (Todhunter et al., 1996). Early in vitro studies on IL-1 in equine 
joint research identified this cytokine as an inducer of PGE2 production 
(May et al., 1992c; May et al., 1992a; May et al., 1989) in chondrocytes and 
synoviocytes, and of protease activity (Spiers et al., 1994) in synoviocytes. 
Since then, IL-1β dependent up-regulation of PGE2 production in 
chondrocytes has been shown to be associated with up-regulation of 
cyclooxygenase-2 (Farley et al., 2005; Tung et al., 2002b) and microsomal 
prostaglandin E synthase-1 expression (Farley et al., 2005). In addition, IL-
1β stimulation of equine chondrocytes results in nitric oxide production 
(Frean et al., 1997). Several studies on equine chondrocytes have 
demonstrated induction of gene expressions of matrix degrading enzymes in 
response to IL-1 (Little et al., 2005; Takafuji et al., 2005; Tung et al., 2002a; 
Richardson & Dodge, 2000; Caron et al., 1996). In addition, inhibition of 
proteoglycan synthesis (Takafuji et al., 2002; Bird et al., 1997; Morris & 
Treadwell, 1994; Platt & Bayliss, 1994; MacDonald et al., 1992), and 
induction of GAG release after IL-1 exposure have been shown in equine 
cartilage explants (Garvican et al., 2008; Gregg et al., 2006; Little et al., 
2005; Takafuji et al., 2002; Frean et al., 2000; Bird et al., 1997; MacDonald 
et al., 1992). These data suggest that IL-1 plays a role in the disease process 
of equine OA.   24 
Synovial fluid from normal equine joints and joints with early and 
chronic joint disease showed an inhibitory effect on synoviocyte PGE2 
production induced by human recombinant IL-1α  in vitro (May et al., 
1992b). However, when the synoviocyte cultures were stimulated with 
human IL-1β the inhibitory effect was only demonstrated in synovial fluid 
from normal joints and joints with early disease, and absent in synovial fluid 
from chronically diseased joints (May et al., 1992b). Therapy aimed at 
reducing the biological action of IL-1 has been investigated in 
experimentally induced equine OA, by the use of as autologous conditioned 
serum (Frisbie et al., 2007), and by gene therapy using equine IL-1Ra and 
an adenoviral vector (Frisbie et al., 2002). In both studies, clinical 
improvement was noted with specific treatment. In addition, the former 
study showed decreased synovial membrane hyperplasia with treatment, but 
no improvement in articular cartilage morphology, and the latter study 
showed improved macroscopic cartilage erosions, preservation of articular 
cartilage proteoglycan content, decreased synovial membrane vascularity, but 
increased synovial membrane lymphocytic infiltrates. Combined 
transduction of equine synoviocytes with IL-1Ra and the anabolic growth 
factor insulin-like growth factor-1 using adenoviral vectors, prevented IL-1β 
induced proteoglycan loss in co-culures with cartilage explants (Haupt et al., 
2005). Furthermore, intra-articular injection with equine IL-1Ra/insulin-
like growth factor-1 adenoviral preparations in joints with microfractured 
chondral defects increased the defect content of proteoglycans (although this 
was also seen in placebo treated joints) and collagen type II, but macroscopic 
and histomorphometric analyses indicated formation of similar repair tissue 
between treated (including placebo) and control joints (Morisset et al., 
2007). 
1.7  Tumour necrosis factor α 
TNFα belongs to the TNF superfamily, which consists of 19 ligands and 30 
receptors (Croft, 2009). The mature protein is formed by cleavage of 
precursor TNFα by TNFα converting enzyme (Black et al., 1997). 
Trimerized TNFα and the homologous cytokine TNFβ are ligands to the 
TNF receptors 1 and 2, the former expressed on most cell types, and 
suggested to be the receptor for soluble TNF, and the latter present mainly 
on immune and endothelial cells, and suggested to be the receptor for 
membrane bound TNF (Aggarwal, 2003; Grell et al., 1995). Depending on 
receptor ligation and activation of different intracellular signalling pathways, 
TNFα is known to either induce apoptosis or transcription factors involved   25 
in the induction of genes of the inflammatory response (Aggarwal, 2003). 
The nucleotide sequence of the equine TNFα gene was demonstrated by Su 
et al. (Su et al., 1991), who  also generated recombinant products that could 
be cleaved into a 17,000 Da protein (Su et al., 1992), consistent with the size 
of human mature TNFα (Aggarwal et al., 1985). The amino acid sequence 
homology between human and equine TNFα was reported to be 87% (Su et 
al., 1992).  
As for IL-1, TNFα has been shown to induce matrix degradation and 
increased gene expression of matrix degrading enzymes in equine 
chondrocytes (Little et al., 2005; Richardson & Dodge, 2000). In 
experimentally induced synovitis, increased immunostaining for TNFα and 
its two receptors have been shown in cells of the synovial membrane and in 
cartilage (Todhunter et al., 1996). Whereas, articular cartilage in acute 
traumatic joint disease showed increased mRNA expression for TNFα, 
cartilage from joints with chronic traumatic disease did not (Trumble et al., 
2001). Increased bioactivity of TNF was found in synovial fluid from joints 
with major intra-articular fractures, but not from joints with synovitis 
(Billinghurst et al., 1995). In a study focusing on cartilage pathology no 
correlation was found between degree of joint damage and TNF activity, 
although a tendency for increased TNF activity was seen with numerous or 
severe changes, and no differences in TNF activity was seen in regard to 
aetiology of lesions (Jouglin et al., 2000). 
Also in normal synovial membrane and articular cartilage TNFα mRNA 
expression has been demonstrated (Trumble et al., 2001). Bioactivity of 
TNF has also been detected in synovial fluid from normal joints 
(Billinghurst et al., 1995) and after exercise (van den Boom et al., 2004). 
1.8  Interleukin-6 
IL-6 belongs to the IL-6 subfamily of cytokines, which all share the signal 
transducing receptor gp130 (Rose-John et al., 2006). By the binding of IL-6 
and the ligand-binding IL-6 α receptor (IL-6Rα) to membrane bound 
gp130, a signalling complex is formed (Boulanger et al., 2003). Soluble 
forms of IL-6Rα (sIL-6Rα) may mediate the effects of IL-6 on cells that 
naturally lack expression of IL-6Rα, a phenomenon referred to as trans-
signalling (Rose-John et al., 2006). In addition, gp130 also exists in soluble 
forms and can bind to IL-6/sIL-6Rα and inhibit induction of biological 
effects (Narazaki et al., 1993). 
Equine IL-6 was originally sequenced and cloned as an 180 amino acid 
mature protein with a predicted molecular mass of 20,471 Da and 77.6%   26 
amino acid homology with human IL-6 (Swiderski et al., 2000). Studies on 
IL-6 in equine joint disease are few, although IL-6 is known to be produced 
in the inflammatory response in experimental lipopolysaccaride induced 
arthritis (Hawkins et al., 1995; Hawkins et al., 1993) and in synovectomy 
induced synovitis (Theoret et al., 1998). Also fibrous tissue of subchondral 
bone cysts show an up-regulation of IL-6 mRNA (von Rechenberg et al., 
2001). In addition, IL-6 mRNA expression is increased in equine 
chondrocytes by IL-1β stimulation (David et al., 2007). 
The exact role of IL-6 in OA and on cartilage metabolism is not clear. 
IL-6 has been found in synovial fluid from human osteoarthritic joints (Doß 
et al., 2007; Kaneko et al., 2000; Remick et al., 1992), and increased IL-6 
activity has been reported in canine OA secondary to cranial cruciate 
ligament rupture (Hay et al., 1997). IL-6 appears to have a 
chondroprotective effect (including reduced cartilage loss) in murine models 
of arthritis (de Hooge et al., 2005), and IL-6 reduces IL-1 induced PGE2 
production (Hauptmann et al., 1991) and stimulates TIMP production 
(Shingu et al., 1995; Shingu et al., 1993; Lotz & Guerne, 1991) in human 
chondrocytes and synoviocytes. On the hand, other studies have shown IL-6 
induced inhibition of proteoglycan synthesis and potentiation of IL-1 
induced proteoglycan catabolism (Jikko et al., 1998; Nietfeld et al., 1990). 
Together with sIL-6Rα, IL-6 induced inhibition of proteoglycan synthesis 
was potentiated (Guerne et al., 1999), and IL-1 induced proteoglycan and 
collagen degradation enhanced (Rowan et al., 2001; Flannery et al., 2000), 
suggesting that the effects from IL-6 can be related to the presence of sIL-
6Rα. 
1.9  High mobility group box protein-1 
HMGB-1 is a chromosomal protein belonging to the HMGB superfamily 
(Bustin, 2001). It is evolutionary conserved, and its nuclear functions include 
nucleosome stabilisation and regulation of  gene transcription (Bianchi & 
Agresti, 2005). Structurally, HMGB-1 is a 215 amino acid protein 
composed of two deoxyribonucleic acid (DNA)-binding domains (the A 
and B boxes) and a carboxyterminal acidic tail (Dumitriu et al., 2005a; 
Bustin, 1999). Whereas the inflammatory action of HMGB-1 resides in the 
B-box (Li et al., 2003), the A-box shows antagonistic action to HMGB-1 
mediated effects (Yang et al., 2004; Kokkola et al., 2003).  
HMGB-1 is classified as an alarmin, an endogenous molecule signalling 
cell or tissue damage (Bianchi, 2007). Extracellular HMGB-1 may arise 
through leakage from damaged or dying cells (Scaffidi et al., 2002; Degryse   27 
et al., 2001). Furthermore, it appears that HMGB-1 release from necrotic 
cells stimulate an inflammatory response (El Mezayen et al., 2007; Scaffidi et 
al., 2002). In addition, immune cells, such macrophages (Wang et al., 
1999a), monocytes (Gardella et al., 2002) and dendritic cells (Dumitriu et al., 
2005b) secrete HMGB-1 upon activation by proinflammatory cytokines 
(TNFα and IL-1β) or bacterial endotoxin, a process that in activated 
monocytes have been shown to involve exocytosis via vesicle mediated 
pathways (Gardella et al., 2002). However, also other types of cells may 
release HMGB-1 in response to inflammatory stimuli (Liu et al., 2006; 
Wang et al., 1999b). Apoptotic cells were shown to firmly bind HMGB-1, 
preventing extracellular release and induction of an inflammatory response 
(Scaffidi et al., 2002). However, subsequently HMGB-1 release has been 
detected also from apoptotic cells (Jiang et al., 2007; Bell et al., 2006). It has 
been shown that the danger signal of HMGB-1 is quenched by caspase- 
triggererd formation of reactive oxygen species and oxidization of HMGB-
1, providing a possible explanation for apoptosis associated immunologic 
tolerance (Kazama et al., 2008). 
The effects from HMGB-1 may be mediated after binding to the 
receptor for advanced glycation end products (Tian et al., 2007; Dumitriu et 
al., 2005b; Loeser et al., 2005; Hori et al., 1995), Toll-like receptor 2, 4 
(Park et al., 2006; Park et al., 2004) and 9 (Ivanov et al., 2007), and 
triggering receptor expressed on myeloid cells-1 (El Mezayen et al., 2007). 
Although HMGB-1 has been found to induce production of 
proinflammatory mediators in monocytes (Andersson et al., 2000) and up-
regulation of IL-1β, IL-8 and TNFα mRNA in neutrophils (Park et al., 
2003), it has lately been proposed that the proinflammatory action of 
HMGB-1 is coupled to complexes formed between HMGB-1 and other 
molecules (such as lipopolysaccarides, IL-1β, single stranded DNA and 
nucleosomes), and that HMGB-1 on its own has mainly mitogenic and 
chemoattractive properties (Bianchi, 2009). 
Investigations on HMGB-1 in equine joint disease are few, and little is 
known about its effects on cartilage. Recently, synovial fluid concentrations 
of HMGB-1 were shown to be increased in Thoroughbred racehorses with 
carpal and fetlock dorsal osteochondral injury compared to normal joints 
(Brown et al., 2009). Furthermore, intra-articular injection with HMGB-1 
induces synovitis in mice (Pullerits et al., 2003), and anti-HMGB-1 
treatment reduces the severity of disease in collagen-induced arthritis in 
mice and rats (Kokkola et al., 2003). Extracellular deposits and/or 
cytoplasmic HMGB-1 have been observed in synovial membrane of human 
chronic inflammatory arthritides, including rheumatoid arthritis (af Klint et   28 
al., 2005; Taniguchi et al., 2003; Kokkola et al., 2002), and synovial fluid 
concentrations of HMGB-1 have been r e p o r t e d  t o  b e  h i g h e r  i n  h u m a n  
rheumatoid arthritis than OA (Taniguchi et al., 2003).  
In osteoarthritic human cartilage marginal increases in HMGB-1 mRNA, 
and HMGB-1 induced increases in PGE2, nitric oxide, IL-6 and IL-8 
production have briefly been reported (Attur et al., 2003). In addition, 
HMGB-1 induced increased activities of mitogen activated protein kinase 
and nuclear factor-kappa B, and MMP-13 production in human 
chondrocyte cultures (Loeser et al., 2005). 
1.10 Joint changes associated with equine OA 
1.10.1  Osteochondral tissues 
Osteoarthritic articular cartilage is typically dull, yellowish discoloured, and, 
depending on severity, shows varying degrees of fibrillation, ulceration, and 
eburnation (Pool & Meagher, 1990) (Fig. 5A). Wear lines, represented by 
fine, parallel and sagitally orientated lines in wide-range hinge joints, have 
been suggested to represent a self-limiting degenerative change in its mild 
forms that under certain circumstances become extensive and contribute to 
generalised cartilage degeneration (Pool & Meagher, 1990). Their presence 
has been positively correlated with exercise, and negatively correlated with 
hydroxylysylpyridinoline crosslinking of collagen (Brama et al., 2000a). In 
fetlock joints, the cartilage degeneration index (CDI) technique (Brommer 
et al., 2003) has been used to assess distribution of cartilage degeneration on 
the proximal surface of the proximal phalanx, and identified the dorsal 
aspect as the initial location for cartilage degeneration (Brommer et al., 
2004). Furthermore, loss of cartilage stiffness has been related to 
degenerative changes in cartilage of the proximal phalanx (Brommer et al., 
2005). 
Microscopically, OA cartilage shows loss of proteoglycans, fragmentation 
of collagen fibrils, splitting and loss of extracellular matrix, chondrocyte 
death and proliferation of viable chondrocytes in adjacent cartilage (Pool & 
Meagher, 1990) (Fig. 5B). A positive correlation between the microscopic 
severity of cartilage changes and extent of apoptotic chondrocytes has been 
demonstrated (Thomas et al., 2007; Kim et al., 2003).   29 
 
Figure 5. (A) Discoloured and fissured cartilage of the dorsal radial facet (arrows) of the third 
carpal bone (photo S. Ekman). (B) Photomicrograph of osteoarthritic cartilage of the radial 
facet showing eroded cartilage and cartilage loss (small arrows), chondrocyte proliferation 
(large arrow), and cracks in the calcified cartilage (arrow heads). 
Increases in thickness of calcified carpal cartilage have been demonstrated at 
sites predisposed to osteochondral injury (Murray et al., 1999). In addition, 
sclerosis of the subchondral bone is often present in areas of cartilage 
degeneration (Anastasiou et al., 2003; Cantley et al., 1999; Pool & Meagher, 
1990). Bone density and stiffness have been shown to be higher in 
pathologic C3 (cartilage degeneration or slab fractures) compared to that of 
C3 in trained and untrained horses (Young et al., 1991), and a 
heterogenenous pattern of focal resorptive lesions and sclerosis of 
subchondral bone has been demonstrated in osteoarthritic third metacarpal 
condyles (Young et al., 2007). Microcracks and microfractures in the 
subchondral bone may be seen in association with severe sclerosis and 
cartilage lesions (Norrdin & Stover, 2006), and a co-localisation of 
microcracks in the calcified cartilage and ingrowth of blood vessels has been 
described in the distal third metacarpal/-tarsal bone (Muir et al., 2006). 
Reactive changes in the joint tissue margins may be seen as periarticular 
osteophytes or as enthesiophytes (Pool & Meagher, 1990). Osteochondral 
fragments (OCF) of bones in the dorsal part of the carpal joints, and on the 
dorsal aspect of the first phalanx, so called chip-fractures (Fig. 6A and B), are 
in most cases thought to arise either from fragmentation of periarticular 
osteophytes at the joint margin, or fragmentation of original joint margins, 
where sclerotic subchondral bone has become necrotic and replaced by 
granulation tissue (Pool & Meagher, 1990). In addition, so called central 
subchondral osteophytes, formed by focal projections of dense bone into the 
calcified cartilage and the deep zone of articular cartilage, have been   30 
described in equine metacarpophalangeal joints with cartilage pathology 
(Olive et al., 2009). 
 
Figure 6. (A) Dorsal osteochondral fragment (OCF) of the proximal phalanx attached to the 
joint capsule. (B) Photomicrograph of OCF showing articular cartilage degeneration (arrows), 
a central core of bone (b), and attachment to the joint capsule (arrow heads). 
1.10.2  Joint capsule and ligaments 
The joint capsule may macroscopically show oedema, congestion, 
discolouration (due to hemosiderosis) and thickening (due to fibrosis) with 
hyperplasia and hypertrophy of synovial villi (Trotter & McIlwraith, 1996; 
Pool & Meagher, 1990). The microscopic appearance of the synovial 
membrane is that of a non-specific inflammatory reaction, and may show 
vascular congestion, hemorrhage, oedema, fibrosis, villi formation, and, less 
commonly, granulocytic and mononuclear/lymphoplasmacytic stromal 
infiltrates (Ronéus et al., 1997; Trotter & McIlwraith, 1996) (Fig. 7A and 
B). In long-standing cases synovial chondromas may form (Pool & Meagher, 
1990). 
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Figure 7. (A) Arthroscopic photograph of fetlock synovial villi with mild to moderate chronic 
hypertrophic synovitis. Multiple superficial wear lines are seen in the articular cartilage (photo 
B. Ronéus). (B) Photomicrograph of synovial membrane in a fetlock joint affected by 
osteoarthritis secondary to fracture of the third metacarpal bone, showing infiltration of 
mononuclear inflammatory cells (arrows), hypercellular lining layer (arrow heads) and fibrosis 
(fi). 
The relation between ligamentous and osteochondral injury in equine carpal 
OA is unclear. However, damage to the medial palmar intercarpal ligament 
is a common finding in horses undergoing carpal arthroscopy (Whitton et 
al., 1997a; Phillips & Wright, 1994; Kannegieter & Colgan, 1993). Whereas 
increased degree of ligament tearing was seen in joints with more severe 
osteochondral damage (Kannegieter & Colgan, 1993), other studies failed to 
detect such a relation (Whitton et al., 1997a; McIlwraith, 1992). 
1.10.3  Synovial fluid 
Currently, there are no routinely used paramenters measured in synovial 
fluid diagnostic for OA. Increases in leukocyte counts and total protein 
concentrations are often minor, and the search for useful biomarkers has 
been extensive (McIlwraith, 2005). 
Although increased concentrations of GAG may be detected in OA 
(Alwan et al., 1991a; Little et al., 1990), other types of injuries may also 
affect GAG concentrations (Palmer et al., 1995b; Alwan et al., 1991a). 
Neither GAG nor aggrecan concentrations have been found to correlate 
with grade of cartilage lesions (Fuller et al., 2001; Skiöldebrand et al., 2001; 
Little et al., 1990). Whereas concentrations of keratan sulphate in chronic 
(but not acute) joint disease were increased compared to normal joints 
(Palmer et al., 1995b), clinically active carpal and fetlock joints (of which the 
majority showed cartilage pathology) showed decreased keratan sulphate 
concentrations and decreased keratan sulphate/GAG ratios compared to the   32 
contralateral joint (Fuller et al., 2001). Furthermore, a negative correlation 
was reported for concentration of keratan sulphate and keratan 
sulphate/GAG ratio and grade of cartilage damage (Fuller et al., 2001). 
Decreased hyaluronan concentrations were also found in clinically active 
joints (Fuller et al., 2001), and in joints affected by traumatic arthritis/OA 
(Tulamo et al., 1996; Hilbert et al., 1984). However, in another study 
concentrations of hyaluronan did not differ between OA and normal joints 
(Little et al., 1990), and both presence (Tulamo et al., 1996) and absence 
(Fuller et al., 2001) of correlations between hyaluronan concentrations and 
degree of cartilage damage has been reported.  
Also, increased COMP concentrations have been reported from 
osteoarthritic equine joints (Arai et al., 2005). Presence of moderate cartilage 
lesions in the middle carpal joint were associated with decreased COMP 
concentrations in Standardbred trotters, but increased concentrations in 
riding horses (Skiöldebrand et al., 2001). Neither concentrations of COMP 
nor collagen type II correlated with grade of cartilage lesions (Skiöldebrand 
et al., 2001), although detection of the collagen type II degradation 
neoepitope C2C was correlated to the severity of joint injury in carpal and 
fetlock joints with OCF (Trumble et al., 2009). Furthermore, in carpal joints 
with osteochondral injury both increased COMP (Skiöldebrand et al., 
2005), CS 846, total protein concentrations (Frisbie et al., 1999) and bone 
alkaline phosphatase (Trumble et al., 2008) have been found, as well as 
increased chondroitin sulphate chain length and decreased hyaluronan chain 
length (Brown et al., 2007). 
A positive correlation between bone alkaline phosphatase and grade of 
cartilage lesions has also been found (Fuller et al., 2001), suggesting that   
bone derived markers are of value to evalualte in OA.  
When OA is induced experimentally (osteochondral defect created 
surgically followed by treadmill exercise) an inflammatory response,   
increased bone formation and metabolism of GAG and collagen is induced, 
reflected by increased concentrations of PGE2, osteocalcin, CS 846, and 
markers of collagen synthesis and degradation (Frisbie et al., 2008). 
Investigations of presence of inflammatory mediators, proteolytic enzymes, 
and enzyme inhibitors in diseased equine joints were partly described in 
sections 1.5-1.7 and 1.9. In addition, increased concentrations of PGE2 
(Kirker-Head et al., 2000; Gibson et al., 1996) and substance P (Kirker-Head 
et al., 2000; Caron et al., 1992) have been found in synovial fluid from OA 
affected equine joints.    33 
2  Aims of thesis 
The general aims of this thesis were to gain a deeper understanding of the 
development of chondral pathology in equine osteoarthritis (OA) by 
obtaining increased knowledge of inflammatory processes in the joint, and 
to investigate proinflammatory cytokines as markers of joint pathology. 
 
The specific aims were: 
 
  Determine synovial fluid concentrations of IL-6 and TNF in 
diseased carpal joints, and investigate possible associations between 
cytokine concentrations and categories of joint lesions (paper I). 
  Determine cellular sources of IL-6 and HMGB-1 in tissues of 
diseased carpal and fetlock joints, and investigate their expressions in 
the synovial membrane in regard to presence of 
chondral/ostochondral pathology (paper II). 
  Characterize morphologic changes in synovial membranes of 
diseased carpal and fetlock joints, to investigate possible relations 
between grade of synovitis and presence of chondral/ostochondral 
pathology (paper II). 
  Investigate metabolic changes in cultured chondrocytes from 
healthy joints after exposure to IL-1β, IL-6 and HMGB-1, and to 
investigate if the responses to cytokine treatment differ between cells 
harvested from differently in vivo loaded sites (paper III).   
  Investigate the effects of IL-1β and IL-6 on HMGB-1 gene 
expression and localisation in cultured chondrocytes (paper IV).   35 
3  Hypotheses 
The following hypotheses were raised for the studies performed on diseased 
joints: 
 
  Concentrations of IL-6 and TNF bioactivities in synovial fluid 
reflect intra-articular pathology (paper I). 
  Dorsal carpal and fetlock osteochondral fragments (OCF) contribute 
to an increased inflammatory response in diseased equine joints 
(paper II). 
 
The following hypotheses were raised for the studies performed on cultured 
chondrocytes: 
 
  Chondrocyte metabolism is affected by exposure to IL-1β, IL-6 and 
HMGB-1 (paper III). 
  A different metabolic response to IL-1β, IL-6 or HMGB-1 can be 
demonstrated in chondrocytes from anatomical sites which show 
different in vivo loading and susceptibility to develop cartilage lesions 
in equine OA (paper III).  
  HMGB-1 is translocated and released from chondrocytes when 
exposed to IL-1β or IL-6 (paper IV).   37 
4  Material and methods 
This section summarises the material and methods used in the studies 
performed for this thesis. Complementary descriptions of the procedures are 
presented in the individual papers. 
4.1  Animals and sample collection (papers I-IV) 
Specimens from diseased joints, were obtained from horses presented for 
arthroscopic examination and/or surgery, and consisted of synovial fluid 
(Paper I), synovial membranes and OCF (paper II), collected under general 
anaesthesia. Synovial fluid from healthy joints were additionally obtained 
from young untrained Standardbred trotters and used as control samples in  
paper I. Represenatitive control material (osteochondral slabs and synovial 
membrane biopsies, paper II) and articular cartilage biopsies (paper III-IV) 
were collected from macroscopically healthy joints from horses presented for 
post mortem examination. The cartilage biopsies were aseptically collected 
as shavings of the dorsal radial facet (DRF) (papers III and IV) and palmar 
condyle (PC) (paper III) of C3 (see Fig. 9A). In several of these joints, 
synovial membrane biopsies and osteochondral slabs were also collected for 
microscopic evaluation from adjacent areas of cartilage biopsies. 
Demographic data for sampled animals and joints are presented in Table 1. 
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Table 1. Demographic data for sampled horses and joints 
Paper Category Breed Horses 
(n=) 
Joint studied 
(n=) 
Age 
(years; mean (range)) 
I  Diseased  STB  40  39 MC, 1 RC  3.6 (2-8) 
    TB  9  3 MC, 6 RC  3.4 (3-5) 
   SWH  2  2  MC  8 
  Healthy  STB  6  6 MC  1  
         
II  Diseased  STB  14  14 MC  3.9 (2-6) 
    SWH  6  2 RC, 3 MCP, 1 MTP  7.5 (2-12) 
   Other  1  1  MCP  10 
  Healthy  SWH  2  1 MC, 1 MCP  6 (2-10) 
   TB  1  1  MC  3 
    STB  1  1 MC  1  
         
III-IV  Healthy  SWH  2  3 MC  2.5 (2-3) 
   Other  2
*  4 MC    4.2 (0.5-8) 
   STB  1  2  MC    1 
STB = Standardbred trotter; SWH = Swedish warmblood riding horse; TB= Thoroughbred 
racehorse; MC = middle carpal; RC = radiocarpal; MCP = metacarpophalangeal; MCT = 
metatarsophalangeal 
*Paper III did not include the ½ year old horse, and paper IV did not include the 8 year old 
horse. 
4.2  Fixation of tissue specimens (papers II-IV) 
Specimens intended for light microscopic evaluation were fixed in 10% 
buffered formalin or 4% phosphate buffered paraformaldehyde. 
Osteochondral material was decalcified in either in  3.4% (w/v) sodium 
formiate and 15.1% (v/v) formic acid, 20% (v/v) formic acid (formalin fixed 
samples), or in 7% (w/v) EDTA with 0.5% (w/v) paraformaldehyde 
(paraformaldehyde fixed samples). Material intended for electron microscopy 
was fixed in 3% phosphate buffered paraformaldehyde. 
4.3  Evaluation of tissues 
4.3.1  Macroscopic assessment (papers I and II) 
To ensure consistency in examinations and tissue handling only one surgeon 
performed the arthroscopic examinations for each paper. The material used   39 
in paper I originated from joints that were macroscopically assessed in regard 
to pathologic findings in a previous study (Skiöldebrand et al., 2001). The 
criteria of grading are presented in Table 2. 
In paper II focus was placed on the presence of OCF, and although 
cartilage lesions were present in all joints without OCF, grading of cartilage 
lesions was not performed as part of the study. Since synovial membrane 
biospsies were collected for further immunohistochemical investigation of 
cytokine production, the synovial membrane reaction was graded 
histologically instead of macroscopically. 
Table 2. Grading of cartilage lesions (paper I) 
Joint tissue  Grade of lesion  Macroscopic finding 
Articular cartilage  Normal  No abnormalities detected 
  Mild  Superficial fraying in a small area 
  Moderate  Fraying over a larger area, erosions 
with focal small areas with denuded 
bone 
  Severe  Fraying, erosions, cartilage loss with 
denuded bone in a large area 
  Chip-fracture  OCF arising in the dorsal parts of 
distal radius, distal RCB, distal IC or 
proximal C3 
Synovial membrane  Normal 
Mild 
No abnormalities detected 
Hyperemia, mild thickening of villi 
  Moderate  Hyperemia, mild thickening of villi, 
focal formation of new villi 
  Severe  Hyperemia, mild thickening of villi, 
focal formation of new villi, adhesions 
between villi 
Intercarpal ligaments  Intact  No abnormalities detected 
  Partial rupture  Fiber fraying in either or both 
ligaments 
OCF = osteochondral fragment; RCB = radial carpal bone; IC = intermediate carpal bone; 
C3 = third carpal bone   
4.3.2  Light microscopy (papers II-IV) 
Haematoxylin and eosin stained sections were used to assess morphology of 
synovial membrane biopsies, OCF, osteochondral slabs, and pellets of three 
dimensional (3D) chondrocyte cultures. 
Grading of inflammatory changes in synovial membranes followed a 
protocol modified from previously described (Krenn et al., 2006), and   40 
assessed lining layer hyperplasia, density of subintimal stromal cells and 
inflammatory infiltrates (paper II). 
Safranin-O and Masson’s trichrome staining were used to assess 
proteoglycan and collagen content in pellets, respectively (paper III). 
4.4  Detection of cytokines in diseased joints 
4.4.1  Bioassays (paper I) 
To detect the bioactivities of IL-6 and TNF in synovial fluid, proliferation 
of IL-6 dependent murine B9 hybridoma cells subclone B13.29
 (Aarden et 
al., 1987) (Fig. 8), and the cytotoxic effect of TNF on the murine fibroblast 
cell line L929 NCTC clone 929 in the presence of actinomycin D (Wang et 
al., 1985) were determined. Cytokine bioactivities were measured by 
analysing the capability of synovial fluid exposed cells to reduce tetrazolium 
salts into formazan derivates, and comparing the results to standard curves 
generated from known concentrations of recombinant human IL-6 and 
TNFα. 
 
Figure 8. B9 cells cultured in the presence (A) and absence (B) of IL-6 (photos M-L. 
Eloranta).   
4.4.2  Immunohistochemistry (paper II) 
Presence and localisation of cytokines in tissue specimens was demonstrated 
with immunohistochemistry. When different fixation and decalcification 
techniques were used for material in the same study, additional material was 
studied to compare levels of antigen detection for the relevant antibodies 
(IL-6 and HMGB-1), and no differences were found. Primary antibodies 
and used concentrations are listed in Table 3. Negative controls were always 
treated with isotype-matched irrelevant antibodies. Light microscopic 
detection of antigen was made by visualization of avidin-biotin-peroxidase   41 
complexes using Sigma Fast™ 3,3’ diaminobenzidine tablet sets (Sigma-
Aldrich Chemical Co., St. Louis, MO, USA). 
Table 3. Primary antibodies used for immunohistochemistry 
Paper Primary  antibody  Dilution 
II  Goat anti-equine IL-6
a 1:100 
II  Rabbit anti-human HMG-1
b 1:500 
aR&D Systems, Abingdon, UK 
bBD Bioscience Pharmingen, San Jose, CA, USA 
4.5  Cytokine stimulation of chondrocyte cultures (papers III and 
IV) 
The procedure of chondrocyte culture is described in detail in papers III and 
IV. Following mechanical mincing of cartilage shavings from DRF and/or 
PC, ECM was digested using collagenase. Cells were expanded in 
monolayer culture (Fig. 9B), then cultured in 3D cell cultures (pellets) using 
protocols modified from previously described (Stenhamre et al., 2008; 
Penick et al., 2005; Tallheden et al., 2004). After 14 days of 3D culture (Fig. 
9C), pellets were treated with proinflammatory cytokines or further cultured 
untreated. For paper III cells were stimulated for a total of 48 h, whereas for 
paper IV cells were stimulated for 48 or 96 h, or 7 days (Table 4). At the 
end of stimulation, cell culture supernatants and/or pellets were collected for 
further analyses. 
 
Figure 9. (A) Sampling sites on the third carpal bone (drf = dorsal radial facet; pc = palmar 
condyle). (B) Chondrocytes cultured in monolayer (photo E. Svala). (C) Chondrocyte pellet 
after 14 days in three dimensional culture. 
 
   42 
Table 4. Protocol for cytokine stimulation 
Cytokine  Concentration  Duration of stimulation 
Recombinant equine IL-1β
a  5 ng/ml  48 h, 96 h, 7 days 
Recombinant equine IL-6
a  5 ng/ml  48 h, 96 h, 7 days 
Recombinant human HMGB-1
a,b  1 µg/ml  48 h 
aR&D Systems, Abingdon, UK 
bSigma-Aldrich, St. Louis, MO, USA 
4.6  Gene expression analyses (papers III and IV) 
4.6.1  Isolation of ribonucleic acid (RNA) 
RNA isolation was performed on 3-4 pooled pellets from each individual 
and sampling site. Mechanical homogenization (bead-milling) of pooled 
pellets was performed using a TissueLyser (Qiagen, Hilden, Germany) on 
samples repeateadly frozen in liquid nitrogen with intervals of 4 minutes. 
Once homogenized, RNA was extracted using QIAzol Lysis Reagent 
(Qiagen) and chloroform. RNA was further purified using RNeasy mini kit 
(Qiagen). Genomic DNA was removed by DNase I (Qiagen). The purity of 
sample RNA was determined by measuring concentrations of RNA 
(NanoDrop® ND-1000 spectrophotometer, Thermo Scientific, 
Wilmington, DE, USA) at 260 and 280 nm. We considered ratios (260/280 
nm) between 1.8-2.1 acceptable (Martin et al., 2001). 
4.6.2  Synthesis of complementary deoxyribonucleic acid (cDNA)  
Total RNA (100 ng/sample) in 20 µl reaction mixtures was used to produce 
cDNA with the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Stockholm, Sweden). cDNA synthesis was performed according 
to the manufacturers’ instructions and by using a 2720 Thermal Cycler 
(Applied Biosystems).  
4.6.3  Quantitative real time reverse transcriptase polymerase chain reaction 
(qRT-PCR) 
The qRT-PCR procedure used in the TaqMan® Gene Expression Assay 
(Applied Biosystems) relies upon the 5′-3′exonuclease activity of Thermus 
aquaticus (Taq) DNA polymerase (Holland et al., 1991). In this system, a 
reporter probe, which is designed to anneal to a specific DNA sequence 
between the forward and reverse primer sites for the target gene, is labelled 
with a fluorescent dye and a quencher. During each amplification cycle, the 
exonuclease activity separates the fluorescent-labelled part of the probe from   43 
the quencher and fluorescence is emitted. The number of cycles required for 
a critical level of fluorescence to be reached (the cycle threshold, CT value) 
is thus dependent on the amount of mRNA for the investigated gene 
present in the sample, as emitted fluorescence is proportional to the 
produced amount of amplicon. The higher the gene expression of a specific 
gene is, the sooner the CT value is reached. 
Human primers and probes were used in the analyses of sex determining 
region on the Y chromosome-related high mobility group box 9 (Sox9), 
HMGB-1 and collagen type II (Applied Biosystems, Sweden). Equine 
primers and reporter sequences were used for versican, collagen type I, 
aggrecan, COMP, MMP-9, MMP-13, ADAMTS-5, TIMP-1 and beta 
glucoronidase (GUSB), the latter used as endogenous control (Applied 
Biosystems) (Table 5). GUSB was selected as housekeeping gene after 
comparing human DNA sequences for housekeeping genes presented in a 
human endogenous control panel (TATAA Biocentre) with equine 
sequences, found in the NCBI (National Centre for Biotechnology 
Information) data base (www.ncbi.nlm.nih.gov), and searching the literature 
for the most commonly used endogenous controls for equine material. The 
efficiencies of all equine specific primers and probes were verified by 
performing 1:2 dilution series of cDNA template and a standard curve. 
Satisfactory stability of GUSB was found throughout a series of experiments 
of pellets treated with hyaluronan, IL-1β and IL-6. 
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Table 5. Equine primer and reporter sequences 
Gene  Primer/probe   Sequence (5′-3′) 
ADAMTS-5
b Forward  primer 
Reverse primer 
Reporter 
TGGCTCACGAAATTGGACATC 
AGGTCTAGCAAACAGTTACCATGACC 
TGGTCCAAATGCACCTC 
Aggrecan
a Forward  primer 
Reverse primer 
Reporter 
GCGAGGCCACCCTAGAG 
CGTGGAGATGGCTCTGTAATGG 
AACACGATGCCTTTCACC 
Coll I
a Forward  primer 
Reverse primer 
Reporter 
GAGGCCGTCCTGTATGCA 
CAAGAGGAGGGCCAAGAAGAAG 
CTGCTGGGATGTCTTC 
COMP
a Forward  primer 
Reverse primer 
Reporter 
GGGCAACGGCTCATACTGT 
GCGAGGGAAGCAGGGATT 
CAACGAGTGCAACGCC 
GUSB
a Forward  primer 
Reverse primer 
Reporter 
GTGACCAACTCCAACTATGAAGCA 
AGGAGTAGTAACTATTCACACAGATGACA 
CATATGGCGCCCCTAGGTC 
MMP-9
b Forward  primer 
Reverse primer 
Reporter 
TTGGACATGCACGACGTCTT 
GAAGCTCACGTAGCCCACTTG 
TACCGAGAGAAAGCTTACTT 
MMP-13
a Forward  primer 
Reverse primer 
Reporter 
GAGCATCCTTCCAAAGACCTTATCT 
GGATAACCTTCCAGAATGTCATAACCA 
TTTAGAGGCCGAAAATT 
TIMP-1
a Forward  primer 
Reverse primer 
Reporter 
CCGCAGCGAGGAGTTTCT 
GTGATGTACAGCTTCTCGTCCAA 
CATCGCCGGACAACTA 
Versican
a Forward  primer 
Reverse primer 
Reporter 
CCTACGTGTGCACCTGTGT 
GCACGTGGCTCCATTGC 
CAGTGTGAGCTTGATTTT 
ADAMTS-5 = a disintegrin and metalloproteinase with thrombospondin motifs 5; Coll I = 
collagen type I; COMP = cartilage oligomeric matrix protein; GUSB = beta glucoronidase; 
MMP-13 = matrix metalloproteinase 13; MMP-9 = matrix metalloproteinase 9; TIMP-1 = 
tissue inhibitor of metalloproteinase 1 
aCustom TaqMan® Gene Expression Assays/Assay by design, Applied Biosystems, Sweden 
bOligos, Applied Biosystems, Sweden 
 
qRT-PCR was performed on duplicate samples of 2.5 ng cDNA/reaction 
using ABI 7900HT (Applied Biosystems) and TaqMan Gene Expression 
master mix (Applied Biosystems). Samples were analysed in ABI Prism® 96-
well Opitcal Reaction plates (Applied Biosystems). Activation of polymerase   45 
was performed at 95°C for 10 minutes, followed by 40 PCR cycles with 
annealing at 60°C, extension at 72°C, and denaturation at 95°C. Data were 
analysed using Sequence Detection System (SDS) 2.2 (Applied Biosystems). 
4.6.4  Evaluation of gene expression  
Relative gene expressions were calculated by using the 2
-ΔΔCT method  
(Livak & Schmittgen, 2001), which is based upon comparisons of CT values 
between target and reference (housekeeping) genes (∆CT) in the evaluated 
sample and a reference sample (calibrator).  
To investigate gene expression profiles in untreated pellets, and to 
determine the overall effect of cytokine treatments a calibrator made of a 
mix of pellets exposed to different teatments was used (paper III). However, 
to evaluate the response to cytokine treatment in individual sites untreated 
control pellets were used as calibrator (papers III and IV). 
4.7  Detection of HMGB-1 in chondrocyte cultures (paper IV) 
4.7.1  Immunohistochemistry 
Immunolocalisation of HMGB-1 in pellets was demonstrated using mouse 
monoclonal 2G7 anti-rat HMGB-1 antibody (Critical Therapeutics Inc., 
Boston, MA, USA; kind gift from Helena Erlandsson Harrris, Karolinska 
Institutet, Stockholm) at a dilution of 1:5000. Treatment of negative 
controls and antigen detection were performed as described in 4.4.2. 
Presence of nuclear versus cytoplasmic and/or extracellular immunostaining 
for HMGB-1 was evaluated. 
4.7.2  Immunelectron microscopy 
Ultrathin sections from one quarter of each pellet were obtained from 
specimens infiltrated with 2.3 M sucrose and frozen at -95°C. Sections were 
placed on carbon-treated formvar coated nickel grids, used as a supporting 
film, and thawed. As primary antibody, rabbit anti-rat HMGB-1 antibody 
(Serotec, Oxford, UK) diluted 1:200 was used. Isotype matched irrelevant 
antibody was applied to a single sample. Quantitative detection of HMGB-1 
was made with gold coated (10 nm) protein A (GE Healtcare, Amersham, 
UK). The densities of HMGB-1 in the different compartments were assessed 
in digitally obtained electron microscopy images by counting numbers of 
gold particles/squared micrometer (Au/µm
2). One image each from a total 
of 15 cells and 10 pericellular areas were evaluated, which according to a   46 
pilot study using cumulative plot (Weibel, 1979) were appropriate sampling 
sizes. 
4.8  Detection of other chondrocyte derived substances (paper 
III) 
4.8.1  Immunoassays 
To complement results from gene expression analyses of aggrecan and 
MMP-13, concentration of the chondroitin sulphate epitope CS 846 (IBEX 
Diagnostics, Montreal, Quebec, Canada) and activated MMP-13 
(Fluorokine E, R&D Systems) were measured in duplicate samples 
according to the manufacturers’ instructions. 
4.8.2  Immunohistochemistry 
To further evaluate effects from cytokine stimulation on COMP metabolism 
in pellets, immunolabelling for COMP was performed using a rabbit anti-
bovine COMP antibody (Hedbom et al., 1992), diluted 1:2000. Treatment 
of negative controls and antigen detection were performed as described in 
4.4.2. 
4.9  Data analyses 
In general, statistic significance was considered when P values were <0.05.   
In paper I, comparisons of cytokine concentrations in synovial fluid 
between categories of joint lesions were analysed using Kruskal-Wallis 
analysis of variance (ANOVA) on ranks or Mann-Whitney rank sum test. 
Dunn’s method with Bonferroni correction was used to isolate groups that 
differed when significance was found by ANOVA on ranks, and in these 
analyses P-values <0.0001 were considered significant. Associations between 
IL-6, TNF and total leukocyte counts and total protein concentrations were 
estimated by Spearman rank order correlation. Analyses were performed 
using SigmaStat 3.0 (SPSS Science Software GmbH, Erkrath, Germany) and 
StatView 5.0.1 (SAS Institute Inc. Copyright© 1992-1998, Cary, USA)
 
software. 
In paper II, differences in immunostaining for IL-6 and HMGB-1 in 
synovial membranes from OA and OCF joints were analysed using the 
Fisher exact test, and differences in synovitis score between OA joints, OCF 
joints, and healthy joints were analysed with Mann Whitney rank sum test 
(SigmaStat 3.0; SPSS Science Software GmbH, Erkrath, Germany).   47 
In paper III, differences in pellet gene expressions and concentrations of 
MMP-13 and CS 846 in pellet supernatants were analysed by ANOVA 
(PROC GLM) in the SAS Software version 9 (SAS Institute Inc., Cary, 
NC, USA). The statistical model included the fixed effects of animal, site, 
treatment, and interactions between site and treatment. Pairwise 
comparisons of least square means between cytokine treated and untreated 
pellets, as well as between sites were tested for significance.  
In paper IV, mean numbers of gold particles per squared micrometer 
(Au/µm
2) in the nucleus, cytoplasm, and pericellular ECM were calculated, 
and nuclear/cytoplasmic (N/C) ratios determined. Due to the low number 
of individuals included in the study statistical tests were not performed.   49 
5  Results 
5.1  Cytokines in synovial fluid (paper I) 
Concentrations of bioactive IL-6 and TNF were measured in synovial fluid 
from a population (n = 51) of athletic horses with carpal pathology. When 
macroscopic OA-like lesions were present, these joints were classified as 
suffering from OA (type I or II, according to the classification by 
McIlwraith, 1996). Several horses did not show cartilage lesions and were 
classified as having traumatic arthritis. 
 
Increased concentrations of IL-6 activity were detected in joints with 
OCF (so called chip-fractures) compared to diseased joints without OCF (P 
< 0.001), and compared to joints with normal, mild or moderate cartilage 
lesions (P < 0.0001). Due to the low number of joints with severe cartilage 
lesions (n= 2) statistical comparisons with this group was not performed, 
however IL-6 was not detected in synovial fluid from these two joints. 
Although highly increased IL-6 activity indicated presence of chip-fracture, 
low or undetectable levels did not exclude their presence. All joints with 
chip-fractures showed some degree of synovitis, however, there was no 
significant difference in IL-6 values between catergories of synovitis. No 
significant correlation was detected between concentrations of IL-6 and 
synovial leukocyte counts, although significance was detected between IL-6 
and total protein concentrations. Activity of IL-6 was not detected in 
synovial fluid from non-lame horses. 
Concentrations of active TNF were low and did not differ between 
categories of joint lesions. Its activity was detected in one synovial fluid 
sample from the non-lame horses.   50 
5.2  Cytokines in joint tissues (paper II) 
Immunohistochemistry was used to investigate the immunolocalisation of 
IL-6 and HMGB-1 in synovial membrane biopsies and osteochondral tissues 
from carpal and metacarpo-/metatarsophalangeal joints with macroscopic 
lesions associated with equine OA (n = 21), and normal joints (n = 4). 
Depending on presence of OCF in diseased joints, a subdivision into OCF 
(n = 10) and OA (n= 11) joints was done, where the former was 
represented by joints with OCF (with or without concurrent cartilage 
lesions) and the latter by joints with cartilage lesions only (absence of OCF). 
Light microscopy was used to morphologically characterize changes in 
sampled tissues. 
 
Immunostaining for IL-6 was demonstrated in cells of synovial 
membranes from all normal joints, and inconsistently demonstrated in cells 
of the synovial membranes from diseased joints. When IL-6 positive cells 
were found, these were present in large numbers and found in the lining 
layer as well as the subintimal stroma and endothelium. Cells with a rounded 
nucleus and abundant cytoplasm, commonly seen in hypercellular lining 
layers were most prominently immunostained. There was no statistical 
difference in frequency of numbers of biopsies with deteced IL-6 between 
OCF and OA joints.  
Whereas nuclear staining for HMGB-1 was the dominating pattern of 
immunostaining in all normal synovial membranes, cytoplasmic and 
widespread extracellular HMGB-1 was detected in 5/10 of synovial 
membrane biopsies from joints with OCF, and in one biopsy from the OA 
joints, however this difference was not statistically significant.  
Immunostaining for IL-6 and HMGB-1 was increased in cartilage of 
OCF compared to normal cartilage. In all examined OCF (n = 8), IL-6 
positive cells were identified, and chondrocytes in the middle and deeper 
zones were often the most intensely immunostained cells. Presence of 
cytoplasmic and/or extracellular HMGB-1 was observed along reduplicated 
tidemarks, and occasionally in areas adjacent to cartilage loss and in fibrous 
tissue. 
Increased grade of synovitis was detected in OA and OCF joints 
compared to normal joints (P = 0.042 and P = 0.013, respectively). 
However, morphologic signs of synovitis in diseased joints was sometimes 
absent (n = 4), most commonly low grade (n = 15), and seldom high grade 
(n = 2). Most often synovitis was related to increases in subintimal stromal 
cells and hypercellular lining layers, and not to increased inflammatory 
infiltrates, which were only seen in two biopsies.   51 
5.3  Effects of cytokines on cultured chondrocytes (paper III and 
IV) 
5.3.1  Effects of IL-1β, IL-6 and HMGB-1 on cartilage matrix metabolism 
(paper III) 
The effects of IL-1β, IL-6 and HMGB-1 on chondrocyte metabolism were 
evaluated in 3D chondocyte cultures (pellets), established with cells 
harvested from the in vivo highly loaded DRF (n=4) and the less loaded PC 
(n=4). The effects were evaluated after 48 h of cytokine treatment by gene 
expression analyses, in part complemented by protein analyses in pellet 
supernatants and of pellet content. 
 
Compared to untreated controls, pellets stimulated with IL-1β showed 
increased gene expression of versican (P<0.0001), MMP-9 (P = 0.0137) and 
TIMP -1 (P = 0.0059), and decreased gene expression of aggrecan (P < 
0.0001), collagen type I (P = 0.0077) and II (P = 0.0082), and COMP (not 
statistically significant, P = 0.0543). In addition, IL-1β treatment induced 
markedly increased gene expression of MMP-13 and ADAMTS-5, as well as 
concentrations of activated MMP-13 in culture supernatant (significance of 
statistical tests not considered due to absence of normally distributed 
residuals), increased COMP immunostaining but decreased safranin-O 
staining of pellets. 
The effects of IL-6 and HMGB-1 treatment on investigated gene 
expressions were variable, although up-regulation of Sox9 was often present 
and statistically increased in HMGB-1 treated pellets (P = 0.012). No other 
significant effects on gene expressions were detected in IL-6 and HMGB-1 
treated pellets compared to controls, and the appearances of pellet safranin-
O staining and immmunostaining for COMP were in most IL-6 and 
HMGB-1 treated pellets similar to that of controls. 
Across treatment, expression of versican was higher in DRF compared to 
PC pellets (P = 0.0020), and the opposite was found for aggrecan (P = 
0.0017). Overall, similar responses to cytokine treatment were found 
between sites. Significant interaction between treatment and site was found 
for aggrecan, where decreased expression was found in IL-1β treated PC 
pellets (P < 0.0001) but not DRF pellets. 
The relative gene expressions of untreated DRF and PC pellets were 
compared, and in the three younger horses higher expression of versican and 
collagen type I was noted in DRF compared to PC pellets, whereas higher 
Sox9, collagen type II and aggrecan expression was noted in PC compared 
to DRF pellets.   52 
5.3.2  Effects of IL-1β and IL-6 on HMGB-1 immunolocalisation and gene 
expression (paper IV) 
The effects of IL-1β, IL-6 on HMGB-1 immunolocalisation and gene 
expression were evaluated in 3D cultured chondrocytes originating from the 
DRF (n=4 or n=3) at three different times (48 h, 96 h and 7 days of 
treatment). Immunolocalisation of HMGB-1 was evaluated by 
immunohistochemistry and immunolelectron microscopy, and gene 
expression was determined using qRT-PCR. A quantitative assessment of 
HMGB-1 translocation and extracellular presence was performed by 
comparing N/C ratios and ECM densities between cytokine treated and 
untreated pellets. 
 
It was not possible to detect a difference in HMGB-1 
immunolocalisation between treated and untreated pellets by 
immunohistochemistry, and presence of nuclear as well as cytoplasmic 
HMGB-1 was detected in treated as well as untreated pellets. Presence of 
extracellular HMGB-1 was sometimes suspected but the exact location was 
made uncertain due to indistinct cytoplasmic borders and/or undiscernable 
nuclei. 
However, by using immunoelectron microscopy increased ECM density 
for HMGB-1, compared to untreated controls, was detected in 6/10 IL-6 
treated pellets and decreased N/C ratios were found in 7/10 IL-6 treated 
pellets. In IL-1β treated pellets, there was an increase in ECM density of 
HMGB-1 in 2/10 pellets and decreased N/C ratios in 5/10 pellets. 
Increased ECM density of HMGB-1 was detected after IL-6 treatment in 
pellets from all horses at some time point, but only in one horse after IL-1β 
treatment. In addition, a trend toward decreased N/C ratios was detected 
with time, particularly in the untreated pellets. 
Changes in HMGB-1 relative gene expression were often small. A clear 
increase (ratio treated/untreated >2) in HMGB-1 gene expression was only 
detected in one IL-1β and one IL-6 treated pellet, although in an additional 
two IL-1β treated samples the ratio (treated/untreated) exceeded 1.7. A clear 
decrease (ratio treated/untreated <0.5) was detected in one IL-1β treated 
pellet. When the gene expression ratios were evaluated together with the 
ratios (treated/untreated) for HMGB-1 immunolocalisation and time, 
increasing nuclear, but not cytoplasmic or ECM, immunolabelling was 
preceded by or concurrent with increased HMGB-1 relative gene 
expression.   53 
6  General discussion 
In order to identify proinflammatory cytokines with possible involvement in 
equine OA, the first two studies of the thesis investigated if IL-6, TNF or 
HMGB-1 could be demonstrated in joints suffering from OA associated 
pathology, and if they were related to a type or grade of joint lesion (i.e. 
could be regarded as a marker of the pathologic finding). By using in vitro 
studies, findings from the initial studies were followed up to investigate 
effects from detected cytokines on cartilage metabolism (paper III), and 
possible causes of extracellular HMGB-1 in cartilage (paper IV). The results 
from the in vitro studies need to be cautiously interpreted in regard to 
possible in vivo effects of investigated cytokines. In vitro-induced phenotype 
alterations of the cultured chondrocytes, and lack of natural biomechanical 
stimuli, interactions between the joint tissues, synovial fluid components and 
inflammatory cells were excluded from the culture system, but may 
influence the outcome of cytokine actions in vivo. 
6.1  Cytokines in diseased joints 
Increased concentrations of IL-6 activity were identified in joints with chip-
fractures, whereas concentrations of TNF activity did not indicate presence 
of a specific category of joint lesion. The increase in IL-6 activity in chip-
fracture joints suggests that IL-6 may be important in the disease process of 
osteochondral fragmentation. Carpal chip-fractures are often removed by 
arthroscopic surgery in order to relieve pain and to prevent progression of 
OA (McIlwraith & Bramlage, 1996), and it is possible that IL-6 is a mediator 
of chip-fracture-induced advancement of OA. IL-6 is known to induce 
bone resorption (Ishimi et al., 1990), and has previously been associated with 
pathologic bone resorption in equine subchondral cystic lesions, indicated by   54 
an upregulation of IL-6 mRNA in fibrous tissue in the cyst centres (von 
Rechenberg et al., 2001). 
 
In experimentally induced synovitis, synovial fluid concentrations of 
TNF and IL-6 activities increase in the early inflammatory response 
(Cornelissen et al., 1998; Hawkins et al., 1995; Hawkins et al., 1993). In 
these studies, peak TNF activity was detected prior to peak synovial fluid 
leukocyte counts (Cornelissen et al., 1998; Hawkins et al., 1995; Hawkins et 
al., 1993), whereas peak IL-6 activity was detected with peak leukocyte 
counts (Hawkins et al., 1995; Hawkins et al., 1993). These findings suggest 
that resident cells (in case of TNF production) as well as infiltrating 
inflammatory cells (in case of IL-6 production) may be important in 
cytokine production. Interestingly, in vitro treatment of equine chondrocytes 
and synoviocyte with lipopolysaccaride did not induce TNF activity, but 
increased concentrations of IL-6 activity in culture media from both cell 
types (Armstrong & Lees, 2002). Thus, both IL-6 and TNF may be 
involved in the inflammatory response of the joint, but clearly, depending 
on experimental conditions, the cytokine response may vary. 
 
In the present study of naturally diseased joints, macroscopic signs of 
synovitis were often found despite no detection of IL-6 and TNF activities 
in the synovial fluid. All joints with chip-fractures showed synovitis 
macroscopically. However, there were no differences in concentrations of 
IL-6 between categories of synovitis, or correlation between IL-6 and 
synovial fluid leukocyte counts, suggesting that IL-6 activity did not 
primarily reflect grade of synovitis, and that other cells than infiltrating 
inflammatory cells may be important in the production of IL-6. Studies on 
human osteoarthritic tissues have demonstrated IL-6 production in several 
cell types including synoviocytes (Field et al., 1991; Guerne et al., 1989), 
plasma cells in the synovial lining layer (Doß et al., 2007), chondrocytes 
(Moos et al., 1999; Guerne et al., 1990), and osteoblasts from subchondral 
bone (Sakao et al., 2008; Massicotte et al., 2002) and osteophytes (Sakao et 
al., 2009). Thus, several joint tissues and cell types could have been 
responsible for IL-6 production in the present study, and this was further 
investigated in paper II. 
  
The results on TNF are in agreement with other studies on naturally 
occurring equine joint disease, where no significant correlation between 
TNF activity and grades of cartilage lesions was found (Jouglin et al., 2000), 
and no increase in TNF activity with chip-fractures or synovitis was seen   55 
(Billinghurst et al., 1995). Neither TNF nor IL-6 bioactivities in synovial 
fluid are strictly associated with clinical signs of joint disease (van den Boom 
et al., 2004; Billinghurst et al., 1995; Hawkins et al., 1995), and TNF activity 
detected in synovial fluid from one of the non-lame horses might have been 
triggered by non-disease-associated mechanisms, such as athletic activity (van 
den Boom et al., 2004). 
 
Only low bioactivity of TNF was detected in the diseased joints. Hence, 
we did not find TNF useful as marker of joint pathology. Since 
concentrations of IL-6 were found in most joints with chip-fractures, IL-6 
could theoretically be regarded as a marker of such lesions. Synovial fluid 
concentrations of TNFα and IL-6 in naturally diseased equine joints have 
previously been determined by using human immunoassays, and it was 
suggested that concentrations of TNFα well predicted, and of IL-6 
excellently predicted joint disease (Bertone et al., 2001). However, the 
amino acid sequence homology between human and equine cytokines, 
reported to be 77.6% for IL-6 (Swiderski et al., 2000) and 87% for TNFα 
(Su et al., 1992), may not be high enough to allow confidence in results 
based upon human immmunoassays. Other researchers have reported 
difficulties in interpreting results based on human immunoassays due to low 
cross-reactivity (Theoret et al., 1998), and claimed that human 
immunoassays do not accurately detect equine cytokines (Armstrong & Lees, 
2002). In the present work, a commersial immunoassay for equine TNFα 
(Endogen, Rockford, IL, USA) was used to detect TNFα in the synovial 
fluid samples previously analyzed for TNF activity. In samples diluted 1:2 or 
1:4 TNFα could not be detected (unpublished results), supporting that 
presence of TNFα was indeed low in analysed samlpes. 
 
In paper II, cells in the synovial membrane were identified as producers 
of IL-6 in healthy as well as in OA and OCF joints. Absence of 
immunostaining for IL-6 in synovial membrane from several diseased joints 
is in accordance with the results in paper I, where IL-6 activity was detected 
in less than half (47%) of the synovial fluid samples. Absence of a difference 
in frequency of IL-6 positive synovial membrane biopsies between OA and 
OCF joints suggested that other joint tissues than the synovial membrane 
may be involved in IL-6 production. This was confirmed by presence of 
immunostaining for IL-6 in cells of all examined OCF. This further suggests 
that the OCF itself is likely to take active part in the inflammatory response 
of diseased joints. 
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The finding of IL-6 positive cells in normal synovial membranes was 
somewhat unexpected since IL-6 was not detected in synovial fluid from 
normal joints (paper I). However, as discussed above, activity of IL-6 has 
been detected by others in synovial fluid from normal equine joints 
(Hawkins et al., 1995; Hawkins et al., 1993), and it is possible that the 
production is related to maintenance of metabolic homeostasis in healthy 
joint. Since the biopsies from normal joints were obtained after death, it 
cannot be excluded that IL-6 production in the synovial membranes could 
be related to post mortem-associated changes, such as tissue hypoxia (Ahn et 
al., 2008; Yan et al., 1995). Compared to chondrocytes, synvoviocytes are 
more sensitive to hypoxia (Schneider et al., 2005), which may explain why 
many synoviocytes but few chondrocytes in normal tissue showed IL-6 
immunostaining.  
 
A cytoplasmic/extracellular pattern of HMGB-1 in the synovial 
membrane was mainly seen in joints with OCF, although it was also present 
in one OA joint. Thus, it may be speculated that presence of OCF 
contributed to release of HMGB-1 in the synovial membrane. Release of 
HMGB-1 in the synovial membrane has been associated with inflammatory 
arthritides such as rheumatoid arthritis (Kokkola et al., 2002). The present 
study showed for the first time that extracellular HMGB-1 may arise from 
cells in the synovial membrane also in osteoarthritic equine joints. A later 
study have further confirmed presence of extracellular HMGB-1 in carpal 
and feltlock joints with OCF by demonstrating significant increased synovial 
fluid concentrations of HMGB-1 in injured compared to normal joints 
(Brown et al., 2009). In synovial fluid from the joints of paper II, HMGB-1 
was detected using an immunoassay (HMGB-1 ELISA kit II, IBL 
International GmbH, Hamburg, Germany) in 7/10 chip fracture joints, and 
in 3/10 (one missing sample) OA joints (unpublished results). 
 
Presence of extracellular HMGB-1 in the OCF further supports a role for 
HMGB-1 in equine OA. Chondrocytes stimulated with HMGB-1 have 
been found to produce MMP-13 (Loeser et al., 2005), which is highly 
efficient in degrading collagen type II (Knäuper et al., 1996), although this 
was not confirmed in the in vitro studies of the present work (paper III). 
Furthermore, HMGB-1 deposits at reduplicated tidemarks may suggest 
involvement in the advancement of subchondral bone, since HMGB-1 has 
been found to have a regulatory role in enchondral ossification (Taniguchi et 
al., 2007). 
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Based upon a small number of joints, increased grade of synovitis was 
detected microscopically in OA and OCF joints compared to normal joints. 
However, in general the synovial reaction in diseased joints was mild. The 
minor infiltration of inflammatory infiltrates is similar to previous 
descriptions in joints with traumatic arthritis and naturally occurring OA 
(Ronéus et al., 1997; Trotter & McIlwraith, 1996). 
 
The material used for papers I and II was obtained from cases of naturally 
occurring and clinically relevant equine traumatic arthritis/OA. The results 
of cytokine detection may be confounded by natural fluctuations in disease 
activity, and presence of joint lesions may have related both to previous or 
ongoing disease activity. Athletic horses suffering from joint disease are often 
treated medically before presented for arthroscopy. This means that the 
majority of joints had received intra-articular medication at some stage 
before arthroscopy. However, in cases of chip-fractures intra-articular 
medication had less often been given. It cannot be excluded that cytokine 
levels in the medicated joints were influenced by treatment. However, little 
is known about how the commonly used antiiflammatory treatments affect 
cytokine production in equine joints in vivo. Recurrence of clinical signs 
despite treatment indicated that previous medication had not managed to 
control the disease process. 
6.2  Effects of cytokines on cultured chondrocytes 
An  in vitro system using 3D chondrocyte cultures was established to 
investigate the effects of the cytokines identified in diseased joints (IL-6 and 
HMGB-1) on cartilage metabolism. In addition, IL-1β was used in the in 
vitro  experiments. Whereas the effects of IL-6 and HMGB-1 on equine 
chondrocytes previously have not been reported, cells were also stimulated 
with IL-1β, which is known to induce a catabolic response in regard to 
proteoglycan metabolism in equine cartilage explants  (Garvican et al., 2008; 
Gregg et al., 2006; Little et al., 2005; Frean et al., 2000; Bird et al., 1997; 
Morris & Treadwell, 1994; Platt & Bayliss, 1994; MacDonald et al., 1992), 
and upregulate matrix degrading enzymes (Little et al., 2005; Takafuji et al., 
2005; Tung et al., 2002a; Richardson & Dodge, 2000; Caron et al., 1996) 
and TIMP-1 (Tung et al., 2002a) in cultured equine chondrocytes. 
 
There are differences in loading patterns between the DRF and PC of 
C3 (Palmer et al., 1994), and these two sites were chosen to study possible 
differences in chondrocyte phenotypes and cytokine-induced responses in   58 
matrix metabolism as an explanation for site-associated cartilage pathology of 
C3. However, in the studies of HMGB-1 immunolocalisation and gene 
expression only DRF derived chondrocytes were studied, as the DRF 
represents an area commonly affected by chondral and osteochondral 
pathology in equine OA (Pool & Meagher, 1990). Only macroscopically 
healthy joints were studied in order to ensure that the phenotypes of 
sampled chondrocytes were not influenced by presence of concurrent intra-
articular disease. 
 
An overall catabolic response on proteoglycan metabolism was 
demonstrated in IL-1β treated pellets, indicated by the reduced safranin-O 
staining compared to untreated control pellets. The effect could partly be 
related to an anti-chondrogenic or dedifferentiating effect induced by IL-1β 
treatment, as the gene expression for Sox9 was decreased and versican 
increased in the majority of IL-1β treated pellets. However, reduced matrix 
proteoglycan content could also relate to increased production of matrix 
degrading enzymes, as increased MMP-9, MMP-13 and ADAMTS-5 gene 
expression was detected in IL-1β treated pellets. Although protein detection 
was not performed for MMP-9 and ADAMTS-5, increased concentrations 
of activated MMP-13 was detected in pellet supernatants from IL-1β treated 
pellets.  
 
Absence of reduced safranin-O staining, and minor changes to gene 
expression for MMP-13 and ADAMTS-5 suggest that IL-6 and HMGB-1 
treatment did not induce substantial matrix degradation. Instead, in IL-6 and 
HMGB-1 treated pellets Sox9 expression was often increased, which 
indicated that IL-6 and HMGB-1 treatment promoted chondrocyte 
differentiation and cartilage formation. This effect was most noticable in the 
two youngest horses, where untreated pellets showed the most 
fibrocartilage-like phenotype (i.e. DRF pellets). 
 
The difference in gene expression profiles in untreated DRF and PC 
pellets of the younger horses, suggested a more hyalin cartilage phenotype in 
PC compared to DRF. This might be associated with different loading 
patterns in vivo, and could indicate a predisposition for the DRF to in vivo 
produce cartilage matrix with inadequate biomechanical properties. The 
DRF is a biomechanically more intensely loaded area than the PC (Palmer et 
al., 1994), and previous studies have shown lowered aggrecan and increased 
decorin synthesis in the DRF compared to PC in strenously, but not 
moderately, trained three to five year old horses (Little et al., 1997). Both   59 
explant and alginate bead cultures from highly loaded ovine cartilage show 
lower aggrecan and higher decorin synthesis compared to cultures from less 
loaded areas, suggesting that loading is of importance in modulating the 
chondrocyte phenotype (Little & Ghosh, 1997). 
  
The notable differences in gene expressions after cytokine treatment in 
the younger horses, may reflect increased responsiveness of young cartilage 
to cytokines, which is in accordance with previous findings on IL-1α 
(Morris & Treadwell, 1994; MacDonald et al., 1992) and TGF-β (Iqbal et 
al., 2000) in equine cartilage explants. Thus, it can be speculated that 
increased cytokine production in vivo will have greater effect on 
chondrocyte metabolism in younger than older individuals.   
 
The similar response to cytokine stimulation in cells from DRF and PC 
does not support site-associated differences to cytokine exposure in vivo, and 
is in accordance with previously reported results based upon stimulation of 
equine cartilage explants with human recombinant IL-1β and TNFα (Little 
et al., 2005). 
 
The 3D cultured chondrocytes appeared relatively insensitive to IL-1β 
and IL-6 treatment in regard to translocation and release of HMGB-1 and 
changes in HMGB-1 gene expression. However, there was a trend for 
increased ECM density of HMGB-1 and decreased HMGB-1 N/C ratios in 
IL-6 treated pellets, which suggests that HMGB-1 was translocated and 
released in response to IL-6 treatment. In contrast, no trend for increased 
ECM density of HMGB-1 was detected in IL-1β treated samples, although 
at 48 h all IL-1β treated pellets showed a decreased N/C ratio. 
 
It can not be excluded that HMGB-1 was released in response to 
cytokine treatment at earlier time points than those investigated. It has been 
shown that monocytes stimulated with lipopolysaccaride redistribute nuclear 
HMGB-1 to cytoplasmic vesicles already within 1 h of exposure (Bonaldi et 
al., 2003), and pituicytes release HMGB-1 after 3-4 h of IL-1 stimulation 
(Wang et al., 1999b). However, in order to simulate the in vivo exposure to 
IL-6 of chondrocytes in chip-fracture joints, where increased bioactivity of 
IL-6 is suspected to remain high for prolonged periods (paper I), the pellet 
cultures were evaluated after prolonged cytokine treatment. Increased 
relative HMGB-1 gene expression preceding or concurrent with increasing 
nuclear HMGB-1 density may indicate that early translocation and release of 
HMGB-1 triggered increased HMGB-1 gene expression to restore nuclear   60 
HMGB-1 concentrations. However, in a previous 18 day study where 
pelleted murine rib chondrocytes of growth cartilage (but not chondrocytes 
from human articular cartilage) released HMGB-1 for up to day 3 of pellet 
culture, increased mRNA levels were not demonstrated (Taniguchi et al., 
2007). In the present study, the finding of increased gene expression and 
increasing nuclear densities was based upon ratios between treated and 
untreated controls, and the clear decrease in N/C ratios in controls needs to 
be taken into account when evaluating the relation between gene expression 
and nuclear densities, as well as cytoplasmic densities. 
 
The reason for decreased N/C ratios with time is unclear. It is possible 
that decreased N/C ratios are associated with increased grade of 
differentiation of the pelleted cells. 3D cultured chondrocytes are known to 
gradually redifferentiate from the fibroblastic phenotype seen during 
expansion in monolayer culture with time (Tallheden et al., 2005; Tallheden 
et al., 2004). In embryonic murine growth cartilage HMGB-1 was not 
demonstrated in resting and proliferating chondrocytes, showed a nuclear 
localisation in prehypertrophic chondrocytes, was translocated to the 
cytoplasm of hypertrophic chondrocytes, and released extracellularly from 
terminal hypertrophic chondrocytes (Taniguchi et al., 2007). Although in 
the present study, growth cartilage was only detected in the deep layer of 
the cartilage in samples from one horse (six months old), all horses were 
young and it is possible that the harvested chondrocytes had retained some 
properties of chondrocytes of growth cartilage. In addition, it can not be 
ruled out that other culture-induced factors also could have influenced the 
N/C ratios. 
 
Based upon the trends for increased ECM density of HMGB-1 and 
decreased HMGB-1 N/C ratios in IL-6 treated pellets, it is possible that 
HMGB-1 is relased in equine articular cartilage as a consequence of IL-6 
stimulation. If so, this could provide a link between high levels of bioactive 
IL-6 in synovial fluid of joints with OCF (paper I) and presence of 
extracellular HMGB-1 in the fragment (paper II).   61 
7  Conclusions 
  Concentrations of bioactive IL-6 were often greatly increased in 
synovial fluid from carpal joints with OCF (chip-fractures). This 
suggests a role for IL-6 in the disease development of affected joints 
and a potential use for IL-6 as a marker of carpal osteochondral 
fragmentation. In contrast, synovial fluid concentrations of TNF 
bioactivity were not associated with any type of joint lesion. 
  Synovial membrane and OCF may both serve as sources of IL-6 and 
extracellular HMGB-1. Production of IL-6 in OCF indicates that 
the fragment is actively involved in the inflammatory response. This 
is also supported by presence of extracellular HMGB-1 in cartilage 
and fibrous tissue of OCF, and possibly by the relatively more 
common finding of extracellular HMGB-1 in synovial membranes 
from chip-fracture joints. 
  Increased synovitis was morphologically detected in OA and OCF 
joints compared to healthy joints, but no difference in grade of 
synovitis was found between OA and OCF joints. 
  IL-1β induced a catabolic matrix response (matrix degradation) in 
chondrocyte pellets, whereas both IL-6 and HMGB-1 appeared to 
promote chondrocyte differentiation and cartilage formation. These 
results propose that the proinflammatory cytokines have different 
roles in cartilage biology, and suggest that the inflammatory response 
of the joint can contribute to cartilage deterioration as well as 
induce processes promoting healing. There was minimal support for 
topographic variation in response to cytokine treatment between 
chondrocytes from different anatomical sites. 
  Trends for increased ECM density of HMGB-1 and lowered 
HMGB-1 N/C ratios in IL-6 treated chondrocyte pellets support 
that HMGB-1 is involved in the inflammatory response of   62 
chondrocytes, and that extracellular HMGB-1 in OCF may be a 
consequence of IL-6 stimulation.   
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8  Future research 
Studies on the inflammatory response and presence of cytokines in equine 
OA is hampered by few species-specific comercially available reagents, such 
as antibodies and immunoassays. However, such reagents would be of great 
help in further clarifying the role of proinflammatory cytokines in the 
development of disease. 
 
To follow up the work performed as part of this thesis, it would be of 
interest to: 
  Investigate presence of IL-1β and IL-1Ra in diseased equine 
joints. Although thought to be of major importance in equine 
OA, no equine studies have examined synovial fluid 
concentrations of IL-1β (or IL-1Ra) in regard to cartilage 
pathology in naturally occurring joint disease, and protein 
detection of IL-1β in joint tissues have relied upon the use of 
non-species specific antibodies. 
  Investigate presence of membrane bound IL-6Rα and gp130 on 
chondrocytes in culture and in cartilage, and of sIL-6Rα and 
gp130 in synovial fluid. Both IL-6 receptors may modulate the 
effects of IL-6, but their presences in equine joints have not been 
studied. 
  Study chondrocyte phenotypes in articular cartilage from the 
DRF and PC in untrained and trained young and old athletic 
horses, with the aim to establish if DRF chondrocytes are 
predisposed to in vivo synthesis of extracellular matrix with 
inferior biomechanical properties compared to cells from PC. 
  Characterize the early HMGB-1 response in chondrocytes 
exposed to IL-1β and IL-6, by evaluating HMGB-1 production   64 
and translocation in pellet cultures prior to 48 hours of 
stimulation. 
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